Design of an engineered ACE2 as a novel therapeutics against COVID-19

DOI10.1016/J.JTBI.2020.110425zbMATH Open1455.92073OpenAlexW3046139892WikidataQ98181857 ScholiaQ98181857MaRDI QIDQ827715

Moslem Jafarisani, Mohammad Reza Rahbar, Saeed Khalili, Alireza Zakeri, Mohammad Javad Rasaee, Abolfazl Jahangiri, Zahra Payandeh, Zahra Sadat Hashemi

Publication date: 13 January 2021

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Full work available at URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387268

zbMATH Keywords

COVID19ACE2in silicoprotein engineeringRBDSARS-CoV-2spike protein

Mathematics Subject Classification ID

Medical applications (general) (92C50)

Related Items (1)

Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors

Uses Software

• Cytoscape
• mCSM
• RINspector

This page was built for publication: Design of an engineered ACE2 as a novel therapeutics against COVID-19

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q827715)